BankPlus Trust Department Invests $555,000 in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

BankPlus Trust Department acquired a new stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 1,379 shares of the pharmaceutical company’s stock, valued at approximately $555,000.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the business. Crestwood Advisors Group LLC grew its position in shares of Vertex Pharmaceuticals by 2.1% in the fourth quarter. Crestwood Advisors Group LLC now owns 5,799 shares of the pharmaceutical company’s stock valued at $2,335,000 after purchasing an additional 121 shares during the period. IFP Advisors Inc lifted its stake in Vertex Pharmaceuticals by 49.2% in the 4th quarter. IFP Advisors Inc now owns 2,756 shares of the pharmaceutical company’s stock valued at $1,114,000 after buying an additional 909 shares in the last quarter. HealthInvest Partners AB boosted its holdings in Vertex Pharmaceuticals by 31.0% in the 4th quarter. HealthInvest Partners AB now owns 22,257 shares of the pharmaceutical company’s stock worth $8,963,000 after buying an additional 5,264 shares during the last quarter. Midwest Capital Advisors LLC purchased a new stake in Vertex Pharmaceuticals during the 4th quarter worth approximately $41,000. Finally, Y Intercept Hong Kong Ltd acquired a new position in shares of Vertex Pharmaceuticals during the fourth quarter valued at approximately $2,169,000. Hedge funds and other institutional investors own 90.96% of the company’s stock.

Insider Transactions at Vertex Pharmaceuticals

In related news, EVP Ourania Tatsis sold 244 shares of Vertex Pharmaceuticals stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $455.06, for a total value of $111,034.64. Following the completion of the transaction, the executive vice president now owns 67,695 shares in the company, valued at $30,805,286.70. The trade was a 0.36 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 0.20% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the company. Piper Sandler lowered their price target on Vertex Pharmaceuticals from $535.00 to $533.00 and set an “overweight” rating on the stock in a research note on Monday, January 27th. JPMorgan Chase & Co. lowered their target price on shares of Vertex Pharmaceuticals from $503.00 to $500.00 and set an “overweight” rating on the stock in a research note on Monday, December 23rd. Needham & Company LLC reiterated a “hold” rating on shares of Vertex Pharmaceuticals in a research report on Tuesday, February 11th. Morgan Stanley boosted their price target on shares of Vertex Pharmaceuticals from $450.00 to $459.00 and gave the stock an “equal weight” rating in a research report on Tuesday, February 11th. Finally, Royal Bank of Canada increased their price objective on shares of Vertex Pharmaceuticals from $407.00 to $408.00 and gave the company a “sector perform” rating in a report on Thursday. Eleven equities research analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Vertex Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $506.70.

Vertex Pharmaceuticals Trading Up 0.8 %

Shares of VRTX stock opened at $484.24 on Monday. The stock has a market capitalization of $124.35 billion, a P/E ratio of -220.11, a price-to-earnings-growth ratio of 2.11 and a beta of 0.41. Vertex Pharmaceuticals Incorporated has a fifty-two week low of $377.85 and a fifty-two week high of $519.88. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.35 and a current ratio of 2.69. The company has a 50 day moving average price of $436.05 and a 200 day moving average price of $460.57.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its earnings results on Monday, February 10th. The pharmaceutical company reported $3.54 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.99 by ($0.45). Vertex Pharmaceuticals had a negative net margin of 4.86% and a negative return on equity of 2.02%. Equities research analysts predict that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current fiscal year.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.